The accelerator, dubbed Mayflower BioVentures, will establish independent cell and gene therapy companies aimed at advancing the development of Mayo Clinic technologies through preclinical and early feasibility studies, according to an Aug. 31 press release.
The goal of Mayflower BioVenture is to advance new cures for serious and complex conditions through cell and gene therapies.
The accelerator’s team will consist of clinical leaders from Mayo Clinic and operational and investment experience from Hibiscus.
Any revenue collected from the accelerator will go toward Mayo Clinic’s patient care, education and research.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
